Vai al contenuto principale
xMedica

NCT06956014ClinicalTrials.gov

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not…

Fase 3810 partecipanti ricercati43 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-05-02; recorded start 2026-09-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Vertanical GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 810 participants (target), run at 43 sites.

How this score is built
  • Enrolment29/40

    810 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale1/10

    Vertanical GmbH has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Patologie

  • Lumbosacral Radiculopathy

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento810 partecipanti ricercati

Sponsor e collaboratori

  • Vertanical GmbH Sponsor

Bracci e interventi

  • VER-01 Dose 1EXPERIMENTAL
  • VER-01 Dose 2EXPERIMENTAL
  • PlaceboPLACEBO_COMPARATOR

Interventi

  • Altro Placebo

    Comparator without active ingredient

  • Farmaco VER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Esiti misurati

  1. Esito primario

    Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Orizzonte temporale From Baseline to Treatment Week 12

Date

Date
Data di inizio22 settembre 2026 (effettiva)
Conclusione primaria1 settembre 2028 (stimata)
Conclusione1 settembre 2028 (stimata)
Prima pubblicazione2 maggio 2025 (effettiva)
Ultimo aggiornamento19 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltanovembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

43 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Central Texas Clinical Research, LLCAustinTexasIn reclutamento
Boston Clinical TrialsBostonMassachusettsIn reclutamento
Bradenton Research CenterBradentonFloridaIn reclutamento
DFW Clinical TrialsCarrolltonTexasIn reclutamento
Epic Medical Research - CarroltonCarrolltonTexasIn reclutamento
Clinitiative - Clinical Trials of South Carolina - CharlestonCharlestonSouth CarolinaIn reclutamento
Epic Medical Research - ChickashaChickashaOklahomaIn reclutamento
Velocity Clinical Research - ClevelandClevelandOhioIn reclutamento
Epic Medical Research - DeSotoDeSotoTexasIn reclutamento
Mountain View Clinical ResearchDenverColoradoIn reclutamento
Innovare Research Group IFriendswoodTexasIn reclutamento
AGA Clinical TrialsHialeahFloridaIn reclutamento
HD Research - Memorial Hermann VillageHoustonTexasIn reclutamento
Perfizien Clinical Research LLCHoustonTexasIn reclutamento
Synergy Groups Medical - Southeast HoustonHoustonTexasIn reclutamento
Green Leaf Clinical TrialsJacksonvilleFloridaIn reclutamento
R & H Clinical ResearchKatyTexasIn reclutamento
Alliance for Multispecialty Research - KnoxvilleKnoxvilleTennesseeIn reclutamento
Epic Clinical Research - LewisvilleLewisvilleTexasIn reclutamento
Central Medical Research InstituteLong BeachCaliforniaIn reclutamento
Tekton Research - LongmontLongmontColoradoIn reclutamento
K2 Medical Research - Maitland IIMaitlandFloridaIn reclutamento
Velocity Clinical Research - MedfordMedfordOregonIn reclutamento
Alma Clinical ResearchMiamiFloridaIn reclutamento
Floridian Research Institute LLC IMiamiFloridaIn reclutamento
AMR MobileMobileAlabamaIn reclutamento
Monroe Biomedical Research - MonroeMonroeNorth CarolinaIn reclutamento
Alliance for Multispecialty Research - NorfolkNorfolkVirginiaIn reclutamento
Conquest Research - Lake NonaOrlandoFloridaIn reclutamento
Alfa Medical Research - Pembroke PinesPembroke PinesFloridaIn reclutamento
Flourish Research - PhiladelphiaPlymouth MeetingPennsylvaniaIn reclutamento
United Medical ResearchPort OrangeFloridaIn reclutamento
Boeson ResearchProvoUtahIn reclutamento
CenExel JBR - Salt Lake CitySalt Lake CityUtahIn reclutamento
Elixia Clinical Research CollaborativeSpringfieldMassachusettsIn reclutamento
Professional Health Care of PinellasSt. PetersburgFloridaIn reclutamento
Velocity Clinical Research - SuffolkSuffolkVirginiaIn reclutamento
Alliance for Multispecialty Research - Tempe ITempeArizonaIn reclutamento
Alliance for Multispecialty Research - Wichita EastWichitaKansasIn reclutamento
Grayline Research CenterWichita FallsTexasIn reclutamento
Progressive Medicine of the Triad, LLCWinston-SalemNorth CarolinaIn reclutamento
Conquest Research - Winter ParkWinter ParkFloridaIn reclutamento
Vitalix ClinicalWorcesterMassachusettsIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 19 novembre 2026

    Centro aggiunto

    11 sites added (43 total)

    3243

  2. 2 novembre 2026

    Centro aggiunto

    9 sites added (32 total)

    2332

  3. 21 ottobre 2026

    Centro aggiunto

    1 site added (23 total)

    2223

  4. 19 ottobre 2026

    Centro aggiunto

    21 sites added (22 total)

    122

  5. 28 settembre 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  6. 28 settembre 2026

    Centro aggiunto

    1 site added (1 total)

    01

  7. 28 settembre 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING